USV to infuse Rs 400 cr for drug formulation plant at VadodaraIllustrative image – not actual.
Oral anti-diabetic drug maker USV will make a fresh investment of Rs 400 crore on a new state-of-art formulations plant at Vadodara in Gujarat. The construction for the new facility at Vadodara will start in the early October 2019, with an initial capital investment of around Rs 400 crore.

The facility will provide employment to more than 350 people. The company will manufacture drugs for diabetes and hypertension segments in this facility. The plant will supply to both the domestic and export markets.

The company has three plants based at Daman and Baddi, manufacturing tablets, capsules, sterile injectables and ophthalmic products, one API plant at Chiplun and biotechnology facility in Nerul, Mumbai. The company is separately investing in a new Active Pharmaceutical Ingredient (API) plant at Ambernath in Maharashtra.

← All latest storiesBack to top →